Autor: |
Holt CB; Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark; Aarhus University, Aarhus, Denmark. Electronic address: charlotte.brinck.holt@clin.au.dk., Hoffmann-Petersen IT; Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark., Hansen TK; Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark., Parving HH; Department of Medical Endocrinology, Rigshospitalet, Copenhagen, Denmark., Thiel S; Department of Biomedicine, Aarhus University, Aarhus, Denmark., Hovind P; Steno Diabetes Center Copenhagen, Gentofte, Denmark., Tarnow L; Steno Diabetes Center, Sjaelland, Denmark., Rossing P; Steno Diabetes Center Copenhagen, Gentofte, Denmark; University of Copenhagen, Copenhagen, Denmark., Østergaard JA; Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark; Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark. |
Abstrakt: |
Competing Interests: Declaration of Competing Interest PR has received consultancy and/or speaking fees from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Gilead, Eli Lilly, Merck, Novo Nordisk and Sanofi Aventis and research grants from AstraZeneca and Novo Nordisk (all honoraria to institution). CBH, ITH, TKH, HHP, ST, PH, LT and JAØ do not have any conflict of interest to declare. |